Sorry for the inconvenience.

Chinese users are only allowed to visit websites which complies with the PIPL (Personal Information Protection Law of the People's Republic of China) effective November 1st.

▲ Scan or click the QR code to visit 三星医疗

The personal information of existing chinese users will be kept until October 29th and will be safely deleted thereafter.

Upgrade browser for full Samsung Healthcare experience

It looks like you may be using a web browser that we don’t support.
Make sure you’re using one of these recommended browsers,
or upgrade your browser by clicking the icons, to get the full Samsung Healthcare experience.

To check which browser you use
본문 바로가기


Experience the advances and contributions we have made

White Paper

Utility of S-Shearwave Imaging™ for the prediction of prostate cancer

  • #Ultrasound System>General Imaging
  • writerProf. Chan Kyo Kim, M.D.
  • date2023.04
Prostate cancer (PCa) is clinically suspected based on the results of digital rectal examination (DRE) and/or elevated serum prostate specific antigen (PSA) level. DRE is subjective and operator dependent, and its sensitivity is questionable for deep or small lesions [1]. It has limited accuracy for staging disease and locating the different foci [2], which are two factors mandatory for planning primary therapy. Despite the low specificity of PSA testing and the low sensitivity of systematic biopsy (SB), these techniques remain the standard of care for PCA diagnosis, mainly because of their widespread availability and low cost [3 6]. The standard for pathologic diagnosis in the men with clinical suspicion of PCa is gray scale transrectal (TRUS) guided 10‒12 core systematic biopsy. However, this diagnostic pathway using gray scale TRUS has limited sensitivity (17‒57%) and specificity (40‒63%) for PCa detection [7 ]. It is difficult to detect prostate lesions accurately as approximately 58% of PCa cases are multifocal, progress along the prostatic capsule, and may not be seen as well defined nodules as in other malignant tumors [8]. Furthermore, suspicious hypoechoi c areas demonstrate PCa in only 9%‒53% of cases [9,10].